Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting

Linch, 1993, Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial, Lancet, 341, 1051, 10.1016/0140-6736(93)92411-L Schmitz, 2002, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet, 359, 2065, 10.1016/S0140-6736(02)08938-9 Kahn, 2011, Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?, Int J Radiat Oncol Biol Phys, 81, 175, 10.1016/j.ijrobp.2010.05.010 Ansell, 2015, Hodgkin lymphoma: diagnosis and treatment, Mayo Clin Proc, 90, 1574, 10.1016/j.mayocp.2015.07.005 Perales, 2015, American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 21, 971, 10.1016/j.bbmt.2015.02.022 Grisold, 2012, Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention, Neuro Oncol, 14, iv45, 10.1093/neuonc/nos203 2017 Moskowitz, 2015, Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 385, 1853, 10.1016/S0140-6736(15)60165-9 Moskowitz, 2016, Brentuximab vedotin after autologous stem cell transplant (ASCT) yields the strongest benefit in Hodgkin lymphoma (HL) patients with ≥ 2 risk factors: results of a multivariate analysis (MVA), Haematologica, 1, 1 Tofthagen, 2013, Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management, Clin J Oncol Nurs, 17, 138, 10.1188/13.CJON.138-144 Chaudhry, 2003, Toxic neuropathy in patients with pre-existing neuropathy, Neurology, 60, 337, 10.1212/01.WNL.0000043691.53710.53 Donohue, 2006, Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia, Oncol Nurs Forum, 33, 347, 10.1188/06.ONF.347-352 Freifeld, 2010, Infectious Diseases Society of America: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis, 52, e56, 10.1093/cid/cir073 Bhatt, 2015, Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades, Clin Lymph Myeloma Leuk, 15, 409, 10.1016/j.clml.2015.02.024 Gyurkocza, 2014, Conditioning regimens for hematopoietic cell transplantation: one size does not fit all, Blood, 124, 344, 10.1182/blood-2014-02-514778 Mills, 1995, BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma, J Clin Oncol, 13, 588, 10.1200/JCO.1995.13.3.588 Baker, 2003, New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors, J Clin Oncol, 21, 1352, 10.1200/JCO.2003.05.108 Bierman, 1993, High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients, Ann Oncol, 4, 767, 10.1093/oxfordjournals.annonc.a058662 Ramsey, 2016, Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma, Br J Haematol, 175, 860, 10.1111/bjh.14316